Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ragistomig, an antibody targeting PD-L1 × 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumistobart, an antibody targeting SIRPA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lancastotug, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Luvagrobart, an antibody targeting NGF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Givastomig, an antibody targeting Claudin 18.2 × 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etakafusp, an antibody targeting CD8.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izastobart, an antibody targeting C5AR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Calotatug, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ebrasodebart, an antibody targeting TMEM219.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emiltatug, an antibody targeting VTCN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aplitabart, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Budoprutug, an antibody targeting CD19.